HGS has a well balanced and deep portfolio of novel drugs directed toward diseases that represent significant unmet medical need. Three of these products are in late-stage development.

We are currently conducting Phase 3 clinical trials of Albuferon® for the treatment of chronic hepatitis C and LymphoStat-B® for the treatment of systemic lupus erythematosus (SLE). ABthrax™ is in late-stage development for the treatment of inhalation anthrax.

Right behind these late-stage products is an emerging high-potential mid-stage pipeline, led by our TRAIL receptor antibodies for the treatment of cancer, and including certain products to which we have substantial financial rights in the GlaxoSmithKline (GSK) clinical pipeline.

	NAME	INDICATION	PHASE 1	PHASE 2	PHASE 3
	Albuferon	Hepatitis C
	LymphoStat-B	SLE
	ABthrax	Anthrax			*
	TRAIL-R mAbs	Cancer
	HGS1029	Cancer	**
	LymphoStat-B	Additional Autoimmune
	Darapladib	Atherosclerosis			***
	Syncria®	Diabetes
	GSK 649868	Sleep Disorders
* Late-Stage/Animal Rule    ** Formerly known as AEG40286    *** Phase 2/3

Click here for brief descriptions of all HGS products in clinical development.